Ryvu Therapeutics SA (RVU) - Total Assets
Based on the latest financial reports, Ryvu Therapeutics SA (RVU) holds total assets worth zł200.96 Million PLN (≈ $55.31 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ryvu Therapeutics SA - Total Assets Trend (2010–2025)
This chart illustrates how Ryvu Therapeutics SA's total assets have evolved over time, based on quarterly financial data. Also see Ryvu Therapeutics SA stock valuation for the company's overall valuation and market capitalisation.
Ryvu Therapeutics SA - Asset Composition Analysis
Current Asset Composition (December 2025)
Ryvu Therapeutics SA's total assets of zł200.96 Million consist of 62.0% current assets and 38.0% non-current assets. Review total liabilities of Ryvu Therapeutics SA to assess the company's total debt and financial obligations.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 26.6% |
| Accounts Receivable | zł20.10 Million | 9.0% |
| Inventory | zł1.33 Million | 0.6% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł6.04 Million | 2.7% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Ryvu Therapeutics SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Ryvu Therapeutics SA (RVU) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ryvu Therapeutics SA's current assets represent 62.0% of total assets in 2025, an increase from 24.9% in 2010.
- Cash Position: Cash and equivalents constituted 26.6% of total assets in 2025, up from 3.2% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is accounts receivable at 9.0% of total assets.
Ryvu Therapeutics SA Competitors by Total Assets
Key competitors of Ryvu Therapeutics SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Ryvu Therapeutics SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.26 | 3.17 | 4.61 |
| Quick Ratio | 2.23 | 3.16 | 4.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł65.15 Million | zł153.56 Million | zł99.25 Million |
Ryvu Therapeutics SA - Advanced Valuation Insights
This section examines the relationship between Ryvu Therapeutics SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.72 |
| Latest Market Cap to Assets Ratio | 0.47 |
| Asset Growth Rate (YoY) | -40.7% |
| Total Assets | zł224.44 Million |
| Market Capitalization | $106.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ryvu Therapeutics SA's assets below their book value (0.47x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Ryvu Therapeutics SA's assets decreased by 40.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Ryvu Therapeutics SA (2010–2025)
The table below shows the annual total assets of Ryvu Therapeutics SA from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | zł224.44 Million ≈ $61.77 Million |
-40.75% |
| 2024-12-31 | zł378.78 Million ≈ $104.24 Million |
-6.06% |
| 2023-12-31 | zł403.20 Million ≈ $110.97 Million |
-15.11% |
| 2022-12-31 | zł474.98 Million ≈ $130.72 Million |
+107.58% |
| 2021-12-31 | zł228.81 Million ≈ $62.97 Million |
-22.60% |
| 2020-12-31 | zł295.64 Million ≈ $81.36 Million |
+61.65% |
| 2019-12-31 | zł182.89 Million ≈ $50.33 Million |
-28.47% |
| 2018-12-31 | zł255.70 Million ≈ $70.37 Million |
+146.88% |
| 2017-12-31 | zł103.57 Million ≈ $28.50 Million |
+16.22% |
| 2016-12-31 | zł89.12 Million ≈ $24.53 Million |
+36.60% |
| 2015-12-31 | zł65.24 Million ≈ $17.96 Million |
+143.41% |
| 2014-12-31 | zł26.80 Million ≈ $7.38 Million |
+49.09% |
| 2013-12-31 | zł17.98 Million ≈ $4.95 Million |
+17.13% |
| 2012-12-31 | zł15.35 Million ≈ $4.22 Million |
-12.31% |
| 2011-12-31 | zł17.50 Million ≈ $4.82 Million |
+70.44% |
| 2010-12-31 | zł10.27 Million ≈ $2.83 Million |
-- |
About Ryvu Therapeutics SA
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myel… Read more